Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NYSE - LSE

CMSC	-0.09%	21.29	$
JRI	-0.4%	12.35	$
BCE	0.26%	23.46	$
CMSD	0%	21.18	$
BCC	-0.03%	78.75	$
GSK	1.08%	50.82	$
RBGPF	0.11%	70.77	$
BTI	-0.27%	56.13	$
VOD	1%	16.04	$
RYCEF	-1.22%	20.5	$
AZN	-1.12%	162.7	$
RIO	-1.43%	103.3	$
RELX	0.66%	36.54	$
NGG	-0.1%	79.35	$
BP	-0.45%	42.15	$

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

BOULEVARD 03.11.2025

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67^th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025.

Text size:

ASH Presentation Details:
Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center)
Publication Number: 81
Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Oral Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
Session Date: Saturday, December 6, 2025
Presentation Time: 10:00 AM - 10:15 AM EST
Location: Orlando Convention Center, W414CD

Presenting Author: Aniket Bankar, MD (Princess Margaret Cancer Centre)
Publication Number: 5588
Title: Comprehensive Analyses of Patient-Reported Outcomes from the Phase 3 VERIFY Study of Rusfertide or Placebo Plus Current Standard of Care for Polycythemia Vera
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)

Presenting Author: Joseph Shatzel, MD (Oregon Health & Science University)
Publication Number: 5587
Title: Should Dermatologic Examinations Become Routine Standard of Care in Patients with Polycythemia Vera, Observations from the Phase 3 VERIFY Study Prior to Rusfertide Exposure
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)

Presenting Author: Naveen Pemmajaru, MD (MD Anderson Cancer Center)
Publication Number: 3810
Title: Long-term Rusfertide Treatment in Polycythemia Vera: Initial Results from the Phase 2
THRIVE Extension Study
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Session Date: Sunday, December 7, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, Inc. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]
+1 833 500 0061

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

M.King--AT

Arizona Tribune - Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Featured

UN, Nepal warn of climate threat after deadly floods

Rescuers dig into tunnel as missing toll from Nepal, China flood nears 3,000

Kanye West Does Not Address Milo Yiannopoulos Detention During New Orleans Concert

Taylor Swift Donation Supports Connecticut Mother Recovering From Serious Roadside Injuries